Core Insights - Hutchison China MediTech Limited (和黄医药) will present updated research data on its self-developed compounds at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting in Berlin from October 17 to 21, 2025 [1] Group 1: Research Presentations - The FRUSICA-2 registration study results for fruquintinib combined with sintilimab in the second-line treatment of locally advanced or metastatic renal cell carcinoma will be presented in a mini-oral session [1] - Further analysis results of the FRUSICA-1 study on fruquintinib for endometrial cancer, as well as the SACHI and SAVANNAH studies on savolitinib for non-small cell lung cancer, will be showcased in poster presentations [1]

Core Viewpoint - The company announced that it will present updated research data on its self-developed compounds at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting in Berlin from October 17 to 21, 2025 [1] Group 1: Research Presentations - The FRUSICA-2 registration study results of fruquintinib combined with sintilimab for second-line treatment of locally advanced or metastatic renal cell carcinoma will be presented in a mini-oral session [1] - Further analysis results of fruquintinib for endometrial cancer from the FRUSICA-1 study will be showcased in a poster presentation [1] - The SACHI and SAVANNAH studies analyzing savolitinib for non-small cell lung cancer will also be presented in the poster session [1]

Core Viewpoint - The company, Hutchison China MediTech Limited (和黄医药), announced that it will present updated research data on its self-developed compounds at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting in Berlin from October 17 to 21, 2025 [1] Group 1: Research Presentations - The FRUSICA-2 registration study results for fruquintinib combined with sintilimab in the second-line treatment of locally advanced or metastatic renal cell carcinoma will be presented during a mini-oral session [1] - Further analysis results of the FRUSICA-1 study on fruquintinib for endometrial cancer, as well as the SACHI and SAVANNAH studies on savolitinib for non-small cell lung cancer, will be showcased in the poster presentation session [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 7%, reaching HKD 26.96 with a trading volume of HKD 352 million, following the announcement of a conference in Shanghai to share R&D progress [1] Group 1: Company Developments - The company will hold a conference on October 31, 2025, in Shanghai to discuss its latest R&D advancements, which will be live-streamed [1] - Dr. Shi Ming, the Executive Vice President and Chief Medical Officer, will present the company's R&D strategy and vision, focusing on the antibody-drug conjugate (ATTC) platform and its first candidate drug HMPL-A251 [1] Group 2: Future Milestones - According to Guotou Securities, several upcoming milestones for the company are noteworthy, with ATTC platform candidates set to enter clinical development soon [1] - The company plans to complete patient recruitment for the SAFFRON III Phase study of Savolitinib in the second half of 2025, with data expected in the first half of 2026 [1] - The SANOVO China Phase III study patient recruitment is also expected to be completed in the second half of 2025 [1] - The company intends to resubmit the new drug application for Solitomab based on the ESLIM-01 study to the National Medical Products Administration in the first half of 2026 [1] - The first ATTC candidate drug is anticipated to initiate clinical trials in China and globally around the end of 2025 [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 7%, reaching HKD 26.96 with a trading volume of HKD 352 million, following the announcement of a conference in Shanghai to discuss its latest R&D progress [1] Group 1: Company Developments - The company will hold a conference on October 31, 2025, in Shanghai to share its R&D strategies and vision, including an overview of its Antibody-Drug Conjugate (ATTC) platform and its first candidate drug HMPL-A251 [1] - The company’s Executive Vice President and Chief Medical Officer, Dr. Shi Ming, will present during the event [1] Group 2: Clinical Development Milestones - Multiple upcoming milestones for the company are anticipated, with ATTC platform candidate drugs set to enter clinical development soon [1] - The company plans to complete patient recruitment for the SAFFRON III Phase study of Savolitinib by the second half of 2025, with data expected in the first half of 2026 [1] - The SANOVO China Phase III study patient recruitment is also expected to be completed in the second half of 2025 [1] - The company intends to resubmit the new drug application for Solitomab based on the ESLIM-01 study in the first half of 2026 [1] - The first ATTC candidate drug is projected to initiate clinical trials in China and globally around the end of 2025 [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) is set to present updated data on its self-developed compounds at two major conferences in September 2025, highlighting its ongoing research in lung cancer treatment [1] Group 1: Upcoming Conferences - The company will present at the 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain from September 6 to 9 [1] - The company will also present at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China from September 10 to 14 [1] Group 2: Research Focus - The latest analysis results of the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of Savolitinib (赛沃替尼) for non-small cell lung cancer will be disclosed at the WCLC [1] - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and Hutchison China MediTech, with commercialization handled by AstraZeneca [1]

Core Viewpoint - HCM's stock rose over 6% to $15.76 following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Conferences - HCM will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Key Research Studies - The latest analysis results of the SACHI and SAVANNAH studies, which evaluate the efficacy of Savolitinib for treating non-small cell lung cancer, will be presented at the WCLC [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel selective and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO meeting [1]

Core Viewpoint - HCM's stock price increased by over 6% to $15.76 following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - HCM will present updated data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for non-small cell lung cancer, will be presented at the WCLC [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel selective and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO meeting [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 5%, currently at 24.68 HKD with a trading volume of 112 million HKD, following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - The company will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib (赛沃替尼), will be presented at the WCLC. Savolitinib is a potent and selective oral MET tyrosine kinase inhibitor co-developed by AstraZeneca and Hutchison China MediTech [1] - The first human Phase I clinical trial data of HMPL-653, a novel, selective, and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO annual meeting [1]

Core Viewpoint - Hutchison China MediTech (00013) saw a stock increase of over 5%, reaching HKD 24.68 with a trading volume of HKD 112 million, following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - The company will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for non-small cell lung cancer, will be disclosed at the WCLC [1] - HMPL-653, a novel selective and potent CSF-1R inhibitor, will have its first human Phase I clinical trial data in Chinese patients with tenosynovial giant cell tumors presented at the CSCO annual meeting [1]